198 related articles for article (PubMed ID: 17653110)
1. MDMA induces EPSP-Spike potentiation in rat ventral hippocampus in vitro via serotonin and noradrenaline release and coactivation of 5-HT4 and beta1 receptors.
Mlinar B; Mascalchi S; Morini R; Giachi F; Corradetti R
Neuropsychopharmacology; 2008 May; 33(6):1464-75. PubMed ID: 17653110
[TBL] [Abstract][Full Text] [Related]
2. 5-HT4 receptor activation induces long-lasting EPSP-spike potentiation in CA1 pyramidal neurons.
Mlinar B; Mascalchi S; Mannaioni G; Morini R; Corradetti R
Eur J Neurosci; 2006 Aug; 24(3):719-31. PubMed ID: 16930402
[TBL] [Abstract][Full Text] [Related]
3. Endogenous 5-HT, released by MDMA through serotonin transporter- and secretory vesicle-dependent mechanisms, reduces hippocampal excitatory synaptic transmission by preferential activation of 5-HT1B receptors located on CA1 pyramidal neurons.
Mlinar B; Corradetti R
Eur J Neurosci; 2003 Sep; 18(6):1559-71. PubMed ID: 14511335
[TBL] [Abstract][Full Text] [Related]
4. Differential modulation of CA1 impulse flow by endogenous serotonin along the hippocampal longitudinal axis.
Mlinar B; Corradetti R
Hippocampus; 2018 Mar; 28(3):217-225. PubMed ID: 29266595
[TBL] [Abstract][Full Text] [Related]
5. Short-term effects of 3,4-methylen-dioxy-metamphetamine (MDMA) on 5-HT(1A) receptors in the rat hippocampus.
Giannaccini G; Betti L; Pirone A; Palego L; Fabiani O; Fabbrini L; Mascia G; Giusti L; Macchia M; Giusiani M; Martini C; Lucacchini A
Neurochem Int; 2007 Dec; 51(8):496-506. PubMed ID: 17602794
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of perforant path input to the CA1 region by serotonin and noradrenaline.
Otmakhova NA; Lewey J; Asrican B; Lisman JE
J Neurophysiol; 2005 Aug; 94(2):1413-22. PubMed ID: 15888529
[TBL] [Abstract][Full Text] [Related]
7. Effects of ethanol and 3,4-methylenedioxymethamphetamine (MDMA) alone or in combination on spontaneous and evoked overflow of dopamine, serotonin and acetylcholine in striatal slices of the rat brain.
Riegert C; Wedekind F; Hamida SB; Rutz S; Rothmaier AK; Jones BC; Cassel JC; Jackisch R
Int J Neuropsychopharmacol; 2008 Sep; 11(6):743-63. PubMed ID: 18248690
[TBL] [Abstract][Full Text] [Related]
8. Acutely applied MDMA enhances long-term potentiation in rat hippocampus involving D1/D5 and 5-HT2 receptors through a polysynaptic mechanism.
Rozas C; Loyola S; Ugarte G; Zeise ML; Reyes-Parada M; Pancetti F; Rojas P; Morales B
Eur Neuropsychopharmacol; 2012 Aug; 22(8):584-95. PubMed ID: 22209363
[TBL] [Abstract][Full Text] [Related]
9. Acceleration of serotonin transporter transport-associated current by 3,4-methylenedioxymethamphetamine (MDMA) under acidic conditions.
Yamauchi Y; Izumi T; Unemura K; Uenishi Y; Nakagawa T; Kaneko S
Neurosci Lett; 2007 Nov; 428(2-3):72-6. PubMed ID: 17949903
[TBL] [Abstract][Full Text] [Related]
10. In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated administration of p-methoxyamphetamine (PMA), but not 3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in serotonin transporter function.
Callaghan PD; Owens WA; Javors MA; Sanchez TA; Jones DJ; Irvine RJ; Daws LC
J Neurochem; 2007 Feb; 100(3):617-27. PubMed ID: 17181558
[TBL] [Abstract][Full Text] [Related]
11. Effect of the selective 5-HT1A receptor antagonist WAY 100635 on the inhibition of e.p.s.ps produced by 5-HT in the CA1 region of rat hippocampal slices.
Pugliese AM; Passani MB; Corradetti R
Br J Pharmacol; 1998 May; 124(1):93-100. PubMed ID: 9630348
[TBL] [Abstract][Full Text] [Related]
12. 3,4-methylenedioxymethamphetamine (MDMA) administration to rats decreases brain tissue serotonin but not serotonin transporter protein and glial fibrillary acidic protein.
Wang X; Baumann MH; Xu H; Rothman RB
Synapse; 2004 Sep; 53(4):240-8. PubMed ID: 15266556
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the translocation of protein kinase C (PKC) by 3,4-methylenedioxymethamphetamine (MDMA/ecstasy) in synaptosomes: evidence for a presynaptic localization involving the serotonin transporter (SERT).
Kramer HK; Poblete JC; Azmitia EC
Neuropsychopharmacology; 1998 Oct; 19(4):265-77. PubMed ID: 9718590
[TBL] [Abstract][Full Text] [Related]
14. Effects of repeated 3,4-methylenedioxymethamphetamine administration on neurotransmitter efflux and sensory-evoked discharge in the ventral posterior medial thalamus.
Starr MA; Page ME; Waterhouse BD
J Pharmacol Exp Ther; 2012 Jan; 340(1):73-82. PubMed ID: 21984836
[TBL] [Abstract][Full Text] [Related]
15. MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment.
Verrico CD; Miller GM; Madras BK
Psychopharmacology (Berl); 2007 Jan; 189(4):489-503. PubMed ID: 16220332
[TBL] [Abstract][Full Text] [Related]
16. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor.
Hewton R; Salem A; Irvine RJ
Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093
[TBL] [Abstract][Full Text] [Related]
17. N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy').
Baumann MH; Clark RD; Budzynski AG; Partilla JS; Blough BE; Rothman RB
Neuropsychopharmacology; 2005 Mar; 30(3):550-60. PubMed ID: 15496938
[TBL] [Abstract][Full Text] [Related]
18. Tolerance to 3,4-methylenedioxymethamphetamine is associated with impaired serotonin release.
Jones K; Brennan KA; Colussi-Mas J; Schenk S
Addict Biol; 2010 Jul; 15(3):289-98. PubMed ID: 20477756
[TBL] [Abstract][Full Text] [Related]
19. Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry.
Callaghan PD; Irvine RJ; Daws LC
Neurochem Int; 2005 Oct; 47(5):350-61. PubMed ID: 15979209
[TBL] [Abstract][Full Text] [Related]
20. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin.
Shankaran M; Gudelsky GA
Pharmacol Biochem Behav; 1998 Dec; 61(4):361-6. PubMed ID: 9802829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
